The DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Open accessAbstract
Cancer remains one of the most formidable challenges in modern medicine, due to its complex and dynamic nature, which demands innovative therapeutic approaches. One major challenge to cancer treatment is the tumour microenvironment and in particular tumour hypoxia (low oxygen levels), which contributes to tumour progression and immune evasion. At the cellular level, this is primarily governed by hypoxia-inducible factor (HIF). HIF is a transcription factor that orchestrates cellular responses to low oxygen levels, driving angiogenesis, metabolic adaptation and immune regulation. HIF’s dysregulation is frequently observed in various cancer types and correlates with increased aggressiveness, metastasis, resistance to therapy and poor patient prognosis. Consequently, understanding the cellular mechanisms underlying HIF activation and its downstream effects has become crucial to developing targeted cancer therapies for improving cancer patient outcomes and represents a key step towards precision medicine. Recent advancements in drug development have led to the emergence of HIF inhibitors, which aim to disrupt HIF-driven processes in cancer providing therapeutic benefit. Here, we provide a review of the molecular mechanisms through which HIF promotes tumour growth and resistance, emphasising the potential clinical benefits of HIF-targeted therapies. This review will discuss the challenges and opportunities associated with translating HIF inhibition into clinical practice, including ongoing clinical trials and future directions in the development of HIF-based cancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can induce cell cycle arrest, upregulate anti-apoptotic proteins, and increase expression of drug resistance genes, such as drug efflux pumps.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Abnormal or poorly organized tumor vasculature also results in hypoxia, which stabilizes hypoxia-inducible factor (HIF) transcription factors that activate signaling pathways regulating survival, angiogenesis, and metabolism [85].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Drugs that block the activity of HIF transcription factors (HIF inhibitors) are currently being investigated as potential therapeutics to target mechanisms that promote survival and therapy resistance in hypoxic tumor cells [85].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple experimental studies provide evidence that reducing or eliminating HIF-α subunit expression can provide therapeutic benefit , particularly in cancer models [270,271] (see Fig. 4).”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [270]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedSamanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedRETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedRETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Research works printed but not linked: 1
- 10.1038/s41577-020-0306 · doi:10.1038/s41577-020-0306
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“Hypoxia-inducible factors (HIFs) are transcription factors activated under low oxygen conditions, playing a critical role in reprogramming cellular metabolism [76, 77].”
BackgroundLorenc, P., Sikorska, A., Molenda, S., Guzniczak, N., Dams‐Kozlowska, H., & Florczak, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117585 · Cited by 153
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Abnormal or poorly organized tumor vasculature also results in hypoxia, which stabilizes hypoxia-inducible factor (HIF) transcription factors that activate signaling pathways regulating survival, angiogenesis, and metabolism [85].”
Gore, M., Kabekkodu, S. P., & Chakrabarty, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189292 · Cited by 49
“…often induced by rapid cell growth, further enhances (HIF-1 α ) activation, which drives additional metabolic adaptations to support survival under E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s E u r op e P M C F und e r s A u t ho r M a nu s c r i p t s low-oxygen conditions [12].”
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
Tufail, M., Jiang, C., & Li, N. (2025) · Military Medical Research · doi:10.1186/s40779-025-00595-2 · Cited by 97
Metadata
- Authors
- Ortmann, B. M.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Ortmann, Brian M
- ORCID
- Ortmann, Brian M
- Venue
- BMJ Oncology
- Publisher
- BMJ
- Published
- 2024-02
- Volume
- 3
- Issue
- 1
- Pages
- e000154
- ISSN
- 2752-7948 (ISSN-L)
- PMC
- PMC11203102
- OpenAlex
- W4391451249
- Cited by
- 67
- References
- 227
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 12
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- BMJ Oncology (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc)
- Funders
- Faculty of Medical Sciences, Newcastle University (NUAcT Fellowship STR/0260/NACT/BO 02)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- hypoxia-inducible factor, tumor hypoxia, tumor microenvironment, HIF inhibitors, angiogenesis, cancer metabolism, immune evasion, treatment resistance, metastasis, HIF-targeted therapy, clinical translation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. https://app.cochat.ai/papers/10.1136/bmjonc-2023-000154
- The paper
- Ortmann, B. M. (2024). Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncology. https://doi.org/10.1136/bmjonc-2023-000154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.